Published online Mar 27, 2022. doi: 10.4240/wjgs.v14.i3.236
Peer-review started: November 1, 2021
First decision: December 4, 2021
Revised: December 12, 2021
Accepted: March 6, 2022
Article in press: March 6, 2022
Published online: March 27, 2022
Processing time: 144 Days and 2.6 Hours
Preventing recurrent common bile duct (CBD) stones is an indispensable study. However, the risk factors for CBD stone recurrence after Endoscopic retrograde cholangiopancreatography (ERCP) are unclear.
The CBD on the cholangiogram is common in every ERCP operations. But CBD morphology has never been classified and discussed.
The aim was to investigate the relationship between CBD morphology and recurrent CBD stones in patients after ERCP.
From February 2020 to January 2021, 502 patients after ERCP at our center were included in the retrospective case-control study. Univariate analysis and multivariate logistic regression analysis were performed to identify risk factors for CBD stone recurrence.
CBD morphology, CBD diameter ≥ 1.5 cm, and endoscopic biliary sphincterotomy with balloon dilation (ESBD) are three independent risk factors for CBD stone recurrence. Furthermore, CBD diameter ≥ 1.5 cm could increase the risk of recurrence and ESBD could decrease the risk of recurrence.
Of the three CBD morphology, patients with the S type had the highest risk of recurrent CBD stones, followed by those with the polyline type and the lowest were the straight type.
A large-scale prospective study should be performed to verified patients with above risk factors could prevent recurrence with medical treatment, such as Ursodeoxycholic acid. And the surveillance period needs further research.